How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,145 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8741. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan

evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-69. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10. De Backer G, Ambrosioni E (...) A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED

2007 NHS Economic Evaluation Database.

8742. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database

Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database Olsen K R, Bilde L, Juhl H H, Kjaer N T, Mosbech H, Evald T, Rasmussen M, Hiladakis H Record Status (...) of the decision model was reported. Outcomes assessed in the review The outcomes estimated from the literature were: descriptive statistics of smokers included in the database; reported abstinence rates in the whole sample as well as in sub-groups of individuals; the mortality rates for smokers (by age, gender and type of smoker); the probability of enrolling again after failing to quit; the lifetime risk of relapse; the natural cessation rate; and life expectancy. Descriptive statistics derived from

2006 NHS Economic Evaluation Database.

8743. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S6-S26. Palmer AJ, Roze S, Foos V, Lurati F, Ray J, Lammert M, et al. Validation Core Diabetes Model. Curr Med Res Opin 2004;20:S27-S40. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079-87 (...) represents good value for money by current standards in the UK. Source of funding Funded by an unrestricted grant from Medtronic AG. Bibliographic details Roze S, Valentine W J, Zakrzewska K E, Palmer A J. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine 2005; 22(9): 1239-1245 PubMedID DOI Other publications of related interest Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F

2005 NHS Economic Evaluation Database.

8744. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

that that of the CYP2C9 genotype. Source of funding None stated. Bibliographic details Schalekamp T, Boink G J, Visser L E, Stricker B H, de Boer A, Klungel O H. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clinical Pharmacology and Therapeutics 2006; 79(6): 511-520 PubMedID DOI Other publications of related interest Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 (...) or CYP2C9*3 alleles on acenocoumarol and phenprocoumon. Thromb Haemost 2004;92:61-6. You JH, Chan FC, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics oriented management of warfarin therapy-a decision analysis. Thromb Haemost 2004;92:590-7. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33. Wadelius M, Chen LY

2006 NHS Economic Evaluation Database.

8745. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II the contribution of leflunomide to efficiency

the contribution of leflunomide to efficiency Schadlich P K, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht J G, Huppertz E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study (...) . Bibliographic details Schadlich P K, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht J G, Huppertz E. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II the contribution of leflunomide to efficiency. PharmacoEconomics 2005; 23(4): 395-420 PubMedID Other publications of related interest Schadlich PK, Zeidler H, Zink A, et al. Modelling cost effectiveness and cost utility of sequential DMARD therapy

2005 NHS Economic Evaluation Database.

8746. Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis

Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Sax P E, Islam R, Walensky R P, Losina E, Weinstein M C, Goldie S J, Sadownik S N, Freedberg K A Record Status This is a critical abstract of an economic (...) . Implications of the study The authors suggested "genotype resistance testing should be performed for all patients with newly diagnosed HIV infection in the United States, with the results used to guide the choice of antiretroviral regimen when treatment is indicated". Source of funding Funded by the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention. Bibliographic details Sax P E, Islam R, Walensky R P, Losina E, Weinstein M C, Goldie S J, Sadownik S N

Full Text available with Trip Pro

2005 NHS Economic Evaluation Database.

8747. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease Rutten-van Molken M P, van Nooten F E, Lindemann M, Caeser M (...) that these results are robust. Funding Supported by ALTANA Pharma AG, Konstanz, Germany. Bibliographic details Rutten-van Molken M P, van Nooten F E, Lindemann M, Caeser M, Calverley P M. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. PharmacoEconomics 2007; 25(8): 695-711 PubMedID Original Paper URL Other publications of related interest Fabbri LM, Sanchez-Toril F, McIvor RA, et al. Effect of roflumilast

2007 NHS Economic Evaluation Database.

8748. Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening

limitation of the analysis was the lack of robust clinical estimates with which to populate the decision model. This introduced uncertainty into the model. Implications of the study The study results suggest that a further evaluation of some model inputs, including prevalence data, would help draw clear conclusions from the comparative analysis of the two screening settings. Source of funding Funded by the UK Department of Health. Bibliographic details Grill E, Uus K, Hessel F, Davies L, Taylor R S (...) , Wasem J, Bamford J. Neonatal hearing screening: modelling cost and effectiveness of hospital- and community-based screening. BMC Health Services Research 2006; 6(14) PubMedID DOI Original Paper URL Other publications of related interest Grill E, Hessel F, Siebert U, et al. Comparing the clinical effectiveness of different newborn hearing strategies. A decision analysis. BMC Public Health 2005;5:12. Davis A, Hind S. The newborn hearing screening programme in England. Int J Pediatr Otolaryngol 2003;67

Full Text available with Trip Pro

2006 NHS Economic Evaluation Database.

8749. The cost-effectiveness of early noninvasive ventilation for ALS patients

The cost-effectiveness of early noninvasive ventilation for ALS patients The cost-effectiveness of early noninvasive ventilation for ALS patients The cost-effectiveness of early noninvasive ventilation for ALS patients Gruis K L, Chernew M E, Brown D L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) of the study conclusions. Implications of the study The study results would appear to support the use of NIPPV for the early management of respiratory failure in patients with ALS. Future trials have to confirm the results of this analysis. Source of funding None stated. Bibliographic details Gruis K L, Chernew M E, Brown D L. The cost-effectiveness of early noninvasive ventilation for ALS patients. BMC Health Services Research 2005; 5(58) PubMedID DOI Original Paper URL Other publications of related

Full Text available with Trip Pro

2005 NHS Economic Evaluation Database.

8750. Effects of omega-3 fatty acids on eye health

Effects of omega-3 fatty acids on eye health Effects of omega-3 fatty acids on eye health Effects of omega-3 fatty acids on eye health Hodge W, Barnes D, Schachter H M, Pan Y, Lowcock E C, Zhang L, Sampson M, Morrison A, Tran K, Miguelez M, Lewin G CRD summary This review evaluated the effects of omega-3 fatty acids on eye health. The authors concluded that there was insufficient evidence to draw firm conclusions and further research is required. This was a well-conducted review and the authors (...) stratify participants by type of cataract. Preliminary observational studies are required to examine the relationship between omega-3 fatty acids and retinal vein/artery occlusion. Funding Agency for Healthcare Research and Quality, contract number 290-02-0021. Bibliographic details Hodge W, Barnes D, Schachter H M, Pan Y, Lowcock E C, Zhang L, Sampson M, Morrison A, Tran K, Miguelez M, Lewin G. Effects of omega-3 fatty acids on eye health. Rockville, MD, USA: Agency for Healthcare Research and Quality

2005 DARE.

8751. A critical review of literature regarding the effectiveness of physical therapy management of hip fracture in elderly persons

A critical review of literature regarding the effectiveness of physical therapy management of hip fracture in elderly persons A critical review of literature regarding the effectiveness of physical therapy management of hip fracture in elderly persons A critical review of literature regarding the effectiveness of physical therapy management of hip fracture in elderly persons Toussant E M, Kohia M CRD summary This review assessed the effectiveness of physical therapy for the treatment of hip (...) be started within 4 months after surgery (Evidence grade C). Research: Future studies need to assess physical therapy in isolation. In addition, studies should focus on the specific location of the hip fracture as opposed to just universal 'hip fractures'. Future research should use standardised definitions of functional recovery (e.g. mobility and activities of daily living). Bibliographic details Toussant E M, Kohia M. A critical review of literature regarding the effectiveness of physical therapy

2005 DARE.

8752. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis Shorr A F, Chung K, Jackson W L, Waterman P E, Kollef M H CRD summary This review evaluated the effects of fluconazole prophylaxis on fungal infections and mortality in critically ill surgical patients. The authors concluded that prophylactic fluconazole appeared (...) . Overall, this was a well-conducted review and the authors' cautious conclusions are likely to be reliable. The stated need for future research appears reasonable. One of the authors had previously received funding from Intrabiotics and is currently receiving funds from Pfizer, Merck Bard and Elan. A second author is on the speakers bureau of Pfizer and Merck. Implications of the review for practice and research Practice: The authors stated that clinicians should make decisions about the use

2005 DARE.

8753. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis

Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis Rakovitch E, Tsao M, Ung Y, Pignol J P, Cheung P, Chow E CRD summary This meta-analysis of 10 (...) of the review for practice and research Practice: The authors did not state any implications for practice. Research: The authors stated that additional studies are needed to directly compare different concurrent chemoradiotherapy regimens in order to identify an optimal regimen with greatest therapeutic benefit for people with inoperable NSCLC. Bibliographic details Rakovitch E, Tsao M, Ung Y, Pignol J P, Cheung P, Chow E. Comparison of the efficacy and acute toxicity of weekly versus daily

2004 DARE.

8754. Evaluating costs for onychomycosis treatments: a practitioner's perspective

suggested that more head-to-head clinical trials should be carried out to corroborate the current findings. Source of funding None stated. Bibliographic details Warshaw E M. Evaluating costs for onychomycosis treatments: a practitioner's perspective. Journal of the American Podiatric Medical Association 2006; 96(1): 38-52 PubMedID Other publications of related interest Because readers are likely to encounter and assess individual publications, NHS EED abstracts reflect the original publication (...) Evaluating costs for onychomycosis treatments: a practitioner's perspective Evaluating costs for onychomycosis treatments: a practitioner's perspective Evaluating costs for onychomycosis treatments: a practitioner's perspective Warshaw E M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2006 NHS Economic Evaluation Database.

8755. A therapeutic HIV vaccine: how good is good enough

and CD4 cell counts of 200 per cubic millimetre or less. New England Journal of Medicine 1997;337:725-33. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making 2002;22: 27-38. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir (...) A therapeutic HIV vaccine: how good is good enough A therapeutic HIV vaccine: how good is good enough A therapeutic HIV vaccine: how good is good enough Walensky R P, Paltiel A D, Goldie S J, Gandhi R T, Weinstein M C, Seage G R, Smith H E, Zhang H, Freedberg K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2004 NHS Economic Evaluation Database.

8756. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings

was restricted to the initial treatment decision. Implications of the study The authors reported that the cost-effectiveness of ART sequencing was most influenced by drug costs and efficacy, rather than the prevalence of resistance. Source of funding Funding received from the French Agence National de Recherches sur le SIDA, the Doris Duke Charitable Foundation, and the National Institute of Allergy and Infectious Diseases. Bibliographic details Walensky R P, Weinstein M C, Yazdanpanah Y, Losina E (...) HIV drug resistance surveillance for prioritizing treatment in resource-limited settings HIV drug resistance surveillance for prioritizing treatment in resource-limited settings HIV drug resistance surveillance for prioritizing treatment in resource-limited settings Walensky R P, Weinstein M C, Yazdanpanah Y, Losina E, Mercincavage L M, Toure S, Divi N, Anglaret X, Goldie S J, Freedberg K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

Full Text available with Trip Pro

2007 NHS Economic Evaluation Database.

8757. Cost-effective diagnosis of ingested foreign bodies

Cost-effective diagnosis of ingested foreign bodies Cost-effective diagnosis of ingested foreign bodies Cost-effective diagnosis of ingested foreign bodies Shrime M G, Johnson P E, Stewart M G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn (...) -effective approach to the diagnosis of ingested foreign bodies. The authors stated that prospective studies should be carried out to validate the current findings. Source of funding None stated. Bibliographic details Shrime M G, Johnson P E, Stewart M G. Cost-effective diagnosis of ingested foreign bodies. Laryngoscope 2007; 117(5): 785-793 PubMedID DOI Other publications of related interest Because readers are likely to encounter and assess individual publications, NHS EED abstracts reflect

2007 NHS Economic Evaluation Database.

8758. Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer

Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Kievit W, Bolster M J, van der Wilt G J, Bult P, Thunnissen F B, Meijer J, Strobbe L J, Klinkenbijl J H, Wobbes T, Adang E M, Beex L V, Tjan Heijnen V C Record Status (...) years, ER- or and PgR-, polychemotherapy. Measure of benefits used in the economic analysis The summary benefit measure was the expected number of life-years (LYs) gained. This was derived using a decision modelling approach. The 10-year overall survival was also reported as a model output. A 4% annual discount rate was applied to assess the present value of future benefits. Direct costs The cost analysis took the perspective of the health care system. It included the direct medical costs of drugs

Full Text available with Trip Pro

2005 NHS Economic Evaluation Database.

8759. Treatment alternatives for chronic hepatitis B viral infection: a cost-effectiveness analysis

clinical decision-making. You should judge whether these treatment strategies are relevant in your own setting, or whether other comparators from other drugs could also be relevant. Validity of estimate of measure of effectiveness The authors reported that a systematic review of the literature had been undertaken, therefore it ensured that the best data available were used in the model. The estimates of effectiveness were derived credibly from the studies identified. The authors used data from (...) of the treatment strategies. These factors may limit extrapolation exercises to other settings. Sensitivity analyses of selected direct costs, to assess the robustness of the estimates used, were conducted and reported. Other issues The authors did not make appropriate comparisons of their findings with those from other studies. Mainly because they stated that their study was the first decision analysis to compare all three currently approved agents for chronic HBV infection, as no model had examined the role

2005 NHS Economic Evaluation Database.

8760. Nurse entrepreneurs - turning initiative into independence

are constantly occurring so be aware that some information may be out-of-date. Have you got what it takes to make it alone? Do you have the skills and tenacity to become self- employed? Setting up your own business is a decision that needs careful consideration. To go it alone you must: ? be passionate about developing an area of interest ? be willing to take risks ? be willing to make a commitment ? be enthusiastic ? believe in yourself and your dream ? have a strong self-image and plenty of self (...) - confidence ? have the drive to achieve and succeed ? have a strong ‘customer’ orientation. Do your homework Before you make your decision, talk to other people who have become self-employed. Ask them about the positive and negative aspects of self-employment. As well as gathering information, you’ll be developing valuable networking skills.Y ou could also consider asking a successful nurse entrepreneur to act as your mentor, so you can benefit from their experience. Y ou’ll also need to do some thorough

2007 Royal College of Nursing

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>